Department of Internal Medicine, Liaoning Tumor Hospital, Shenyang, Liaoning 110042, PR China.
Mol Med Rep. 2013 Jul;8(1):221-6. doi: 10.3892/mmr.2013.1495. Epub 2013 May 28.
Cis‑diamminedichloroplatinum (cisplatin, CDDP)‑containing combination chemotherapy is commonly used for the treatment of non‑small‑cell lung cancer (NSCLC). 2',2'‑Difluorodeoxycytidine (gemcitabine, GEM), an active antineoplastic agent for NSCLC, has been previously reported to be suitable for use in combination with cisplatin in chemotherapy, since their mechanisms may be complementary. In the present study, the sequence‑dependent effects of GEM and CDDP were investigated in the NSCLC cell line, A549. Significantly increased rates of inhibition and cell cycle arrest were observed in the group treated with GEM followed by CDDP, and this treatment plan was demonstrated to represent the most efficient treatment protocol for the A549 NSCLC cell line. Results of the present study are consistent with previous studies in other cell lines and are likely to provide important insight for subsequent studies.
顺式-二氨二氯铂（顺铂，CDDP）联合化疗常用于治疗非小细胞肺癌（NSCLC）。2'，2'-二氟脱氧胞苷（吉西他滨，GEM）是一种用于 NSCLC 的活性抗肿瘤药物，先前有报道称其适用于与顺铂联合化疗，因为它们的作用机制可能互补。在本研究中，研究人员研究了 GEM 和 CDDP 在 NSCLC 细胞系 A549 中的序列依赖性作用。用 GEM 处理后再用 CDDP 处理的组观察到抑制率和细胞周期停滞率显著增加，该治疗方案被证明是针对 A549 NSCLC 细胞系最有效的治疗方案。本研究结果与其他细胞系的先前研究一致，可能为后续研究提供重要见解。
